Chen, PeiliBakke, DanikaKolodziej, LaurenLodolce, JamesWeber, Christopher R.Boone, David L.Toback, F. Gary2016-12-152016-12-152015-10Chen, P., Bakke, D., Kolodziej, L., Lodolce, J., Weber, C. R., Boone, D. L., & Toback, F. G. (2015). Antrum Mucosal Protein-18 Peptide Targets Tight Junctions to Protect and Heal Barrier Structure and Function in Models of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 21(10), 2393–2402. https://doi.org/10.1097/MIB.00000000000004991078-0998 1536-4844https://hdl.handle.net/1805/11629Background: A peptide derived from Antrum Mucosal Protein (AMP)-18 (gastrokine-1) reduces the extent of mucosal erosions and clinical severity in mice with dextran sulfate sodium (DSS)-induced colonic injury. The present study set out to determine if AMP peptide was also therapeutic for immune- and cytokine-mediated mouse models of intestinal injury and inflammatory bowel diseases (IBD) by enhancing and stabilizing tight junctions (TJs). Methods: Therapeutic effects of AMP peptide were examined in interleukin-10 deficient and a T cell adoptive transfer models of colitis in immunodeficient recombinase activating gene-1 knock-out (RAG-1−/−) mice. Mechanisms by which AMP peptide enhances barrier function and structure were studied ex vivo using intestine and colon from mice given lipopolysaccharide (LPS), and in AMP-18 deficient mice given DSS. Results: In interleukin-10 deficient mice given piroxicam, AMP peptide enhanced recovery after weight loss, protected against colon shortening and segmental dilation, and reduced the colitis activity score. In the T cell transfer model, treatment with the peptide protected against colon shortening. In mice given LPS in vivo to induce gut injury, AMP peptide prevented the onset of, and reversed established intestinal hyperpermeability by targeting TJ proteins and perijunctional actin.en-USPublisher's PolicyAntrum Mucosal Protein (AMP)-18gastrokine-1IBDTight JunctionsZO-1Article